信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

盘前交易 05-26 04:41:18 EDT

4.44

+0.07

+1.60%

最高4.46	最低4.27	成交量37.38万
今开4.27	昨收4.37	日振幅4.23%
总市值2.13亿	流通市值1.52亿	总股本4,788万
成交额163.48万	换手率1.09%	流通股本3,423万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":4.44,"timestamp":1779480000000,"preClose":4.37,"halted":0,"volume":373849,"delay":0,"changeRate":0.01601830663615567,"floatShares":34233044,"shares":47884104,"eps":0.209971,"marketStatus":"盘前交易","change":0.07,"latestTime":"05-26 04:41:18 EDT","open":4.27,"high":4.455,"low":4.27,"amount":1634839.5834455998,"amplitude":0.042334,"askPrice":4.78,"askSize":230,"bidPrice":3.8,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.209971,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779802200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":4.44,"dividendRate":0.040541,"postHourTrading":{"tag":"盘后","latestPrice":4.4762,"preClose":4.44,"latestTime":"18:32 EDT","volume":3697,"amount":16425.61,"timestamp":1779489179324,"change":0.0362,"changeRate":0.008153,"amplitude":0.016464},"volumeRatio":1.3697383909391898,"impliedVol":0.1116,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2637634193","title":"Inovio中国合作伙伴III期试验成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2637634193","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637634193?lang=zh_cn&edition=full","pubTime":"2026-05-23 03:31","pubTimestamp":1779478260,"startTime":"0","endTime":"0","summary":"Inovio Pharmaceuticals股价走高，此前其中国合作伙伴ApolloBio在治疗宫颈不典型增生的治疗性DNA疫苗VGX-3100的III期关键性试验中取得成功。该试验达到了第36周复合缓解率的主要终点。Inovio于2018年将VGX-3100授权给ApolloBio，后者承担开发费用，Inovio有权获得最高2000万美元的监管里程碑付款及大中华区净销售额的双位数分层特许权使用费。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-23/doc-inhyvhua5796224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334314","title":"阿斯利康将在ASCO 2026公布多项III期数据，涵盖肝癌、乳腺癌、膀胱癌及罕见病疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334314","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637334314?lang=zh_cn&edition=full","pubTime":"2026-05-22 23:33","pubTimestamp":1779463980,"startTime":"0","endTime":"0","summary":"阿斯利康于5月22日宣布，将在5月29日至6月2日举行的2026年美国临床肿瘤学会年会上，公布超过85篇摘要，涵盖10款已获批药物和13款潜在新药，其中包括25项口头报告。　　在肝癌方面，将公布EMERALD-3 III期试验结果。　　在膀胱癌方面，将公布POTOMAC III期试验的5年总生存期分析，该试验评估了Imfinzi联合卡介苗治疗高危非肌层浸润性膀胱癌的疗效。　　在罕见病方面，将展示anselamimab的III期临床项目数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyuwee5028220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B3T34201.USD","LU2237443978.SGD","LU0289739699.SGD","BK4588","LU2237443465.HKD","LU0109394709.USD","AZNH","LU1829250122.USD","LU2236285917.USD","BK4007","LU2462157665.USD","LU0889565916.HKD","LU2456880835.USD","LU2237443382.USD","LU2237443895.HKD","LU2237443549.SGD","LU2417539215.USD","LU0058720904.USD","AZN","BK4134","III","LU0320765992.SGD","BK4585","LU2237443622.USD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637362263","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超5% 恩沃利单抗新适应症III期临床完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637362263","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637362263?lang=zh_cn&edition=full","pubTime":"2026-05-22 11:31","pubTimestamp":1779420681,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超4%，截至发稿，涨4.32%，报9.18港元，成交额811.35万港元。消息面上，5月22日，康宁杰瑞生物制药宣布，恩维达新辅助/辅助治疗可切除非小细胞肺癌的Ⅲ期临床研究，已完成全部患者入组。这一里程碑标志着恩维达在早期肺癌围手术期治疗领域取得重要进展，有望为肺癌患者带来更便捷、更安全的皮下免疫治疗新方案。目前恩维达还有多个临床研究在进行中，进一步拓展适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","BK4588","BK4134","VXUS","BK1161","BK4585","BK1574","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334485","title":"安捷伦推出1290 Infinity III荧光检测器，实现UHPLC速度下的高信度痕量分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334485","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637334485?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:07","pubTimestamp":1779372420,"startTime":"0","endTime":"0","summary":"安捷伦科技公司宣布推出Agilent 1290 Infinity III荧光检测器。这款新型检测器专为现代超高效液相色谱工作流程设计，将荧光检测技术带入UHPLC时代，为实验室提供痕量分析所需的更高置信度。传统荧光检测器并非为UHPLC方法的窄峰和快速分离而设计。1290 Infinity III FLD通过专为现代UHPLC优化的设计填补了这一空白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-21/doc-inhysnxc6275941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637336990","title":"思路迪医药股份(01244)：恩维达®非小细胞肺癌新辅助╱辅助治疗III期临床研究提前完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637336990","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637336990?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:43","pubTimestamp":1779367407,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份 发布公告，本公司与康宁杰瑞生物制药共同开发的恩维达用于可切除非小细胞肺癌患者新辅助╱辅助治疗的随机、对照、双盲、多中心III期临床研究已提前完成入组。本次III期临床研究由天津医科大学肿瘤医院王长利教授担任主要研究者，在全国约60家临床研究中心开展，计划入组约390例可切除III期非小细胞肺癌患者，实际入组人数符合研究方案要求，已提前完成入组工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","BK1161","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636285087","title":"Bimzelx头对头III期研究告捷，斑块状银屑病关节炎指标显著优于Skyrizi","url":"https://stock-news.laohu8.com/highlight/detail?id=2636285087","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636285087?lang=zh_cn&edition=full","pubTime":"2026-05-19 23:01","pubTimestamp":1779202886,"startTime":"0","endTime":"0","summary":"　　比利时生物制药企业优时比公布了其IL-17A/IL-17F抑制剂Bimzelx的III期BE BOLD研究详细数据。结果显示，Bimzelx在治疗活动性银屑病关节炎患者的关键指标上，击败了艾伯维的重磅IL-23抑制剂Skyrizi。早在治疗第4周，Bimzelx组达到ACR50的患者比例便显著高于Skyrizi组。Bimzelx治疗组念珠菌感染的发生率较高，但均为轻中度，未导致停药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-19/doc-inhymytc2158400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636863428","title":"港股异动 | 维立志博-B(09887)早盘涨超4% 维利信™治疗晚期肺外神经内分泌癌III期临床研究获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2636863428","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636863428?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:53","pubTimestamp":1779155590,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B早盘涨超4%，截至发稿，涨3.21%，报64.35港元，成交额897.51万港元。消息面上，5月19日，维立志博-B发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK4585","HK0000252152.HKD","VXUS","BK4134","HK0000500386.USD","BK4588","III","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022270","title":"维立志博-B(09887)：维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)治疗晚期肺外神经内分泌癌的III期临床研究获得CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636022270?lang=zh_cn&edition=full","pubTime":"2026-05-19 07:18","pubTimestamp":1779146304,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。奥帕替苏米单抗已在肺外神经内分泌癌、非小细胞肺癌、小细胞肺癌及胆道癌四个适应症的注册性或II 期临床试验中展示出全球首创或同类最优潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4023","PD","HK0000252160.HKD","LU1169590202.USD","LU1223082519.USD","HK0000252152.HKD","BK4134","CDE","BK4017","LU1169589451.USD","LU1223082196.USD","HK0000500386.USD","BK1161","09887","LU1223083913.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635979297","title":"美国宇航局披露Artemis III任务细节：近地轨道对接演练，测试未来登月所需系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2635979297","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635979297?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:50","pubTimestamp":1778748613,"startTime":"0","endTime":"0","summary":"IT之家 5 月 14 日消息，美国宇航局本周三公布“阿尔忒弥斯 3 号”任务初步计划，不再直接承担登月任务，改为 2027 年执行近地轨道测试。美国宇航局今年 3 月宣布 Artemis III 任务不再直接登月，而是作为后续载人登月前的过渡测试。这次调整延续了美国宇航局局长 Jared Isaacman 3 个月前推动的 Artemis 计划改组方向，目标是加快最终登月进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8t7bXxsdWSw","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635761328","title":"港股异动 | 来凯医药-B(02105)午前涨超5% LAE002 III期临床到达终点 将提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2635761328","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635761328?lang=zh_cn&edition=full","pubTime":"2026-05-14 11:58","pubTimestamp":1778731118,"startTime":"0","endTime":"0","summary":"消息面上，来凯医药核心产品AKT抑制剂LAE002治疗乳腺癌的III期临床试验已于4月15日宣布达到主要终点。根据公司计划，将协同合作伙伴齐鲁制药于近期向国家药监局提交新药上市申请。齐鲁制药也于4月30日宣布将推进该药的国内上市申请。作为回报，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","IPOS","02105","BK4588","BK4585","BK1161","III","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278901","title":"新股前瞻|大单品进入III期临床，现金流告急的质肽生物就差临门一脚？","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278901","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635278901?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:23","pubTimestamp":1778639015,"startTime":"0","endTime":"0","summary":"目前，该药物正在中国开展减重II期临床，有望填补口服多肽GLP-1市场空白。公司已于2026年1月在中国完成了ZT002用于肥胖症治疗的III期临床试验的首例患者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159399","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634476449","title":"港股异动 | 银诺医药-B(02591)午前涨超43% Suba的III期减重数据预计2026年年底前公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2634476449","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634476449?lang=zh_cn&edition=full","pubTime":"2026-05-11 11:37","pubTimestamp":1778470647,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B午前涨超43%，截至发稿，涨42.21%，报17.99港元，成交额1.73亿港元。消息面上，银诺医药年度业绩显示，2025 年实现收入1.32亿元，亏损3.41亿元。值得注意的是，银诺医药基石投资者的禁售期将于2026年5月14日届满，相关股份将于5月15日正式解禁流通。Suba的III期减重数据预计2026年年底前公布。治疗肥胖及超重的III期临床研究，已于2025年完成患者入组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"68e9cc22a457e84dfc55ae6520639fb8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4134","02591","VXUS","BK1161","BK4585","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633182090","title":"翰宇药业(300199.SZ)：司美格鲁肽注射液减重及降糖两项国内适应症的III期临床试验均获得达到等效标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2633182090","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633182090?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:13","pubTimestamp":1778065991,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，近日，公司司美格鲁肽注射液取得了III期临床数据，数据显示，该药物的减重及降糖两项国内适应症的III期临床试验均获得了达到等效标准。公司司美格鲁肽注射液在国内进行了两项临床试验，分别是：一项在二甲双胍单药治疗血糖控制不佳的2型糖尿病患者中比较HY310注射液与诺和泰®治疗32周的疗效和安全性的多中心、随机、开放设计的III期临床研究。一项在肥胖患者中比较HY310注射液与诺和盈®治疗44周的疗效和安全性的多中心、随机、开放设计的III期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300199","BK0028","BK0070","BK0188","BK0239","BK4134","III","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629896382","title":"港股异动 | 歌礼制药-B(01672)午前涨超4% 核心管线ASC30即将启动III期注册临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2629896382","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629896382?lang=zh_cn&edition=full","pubTime":"2026-04-24 11:10","pubTimestamp":1777000213,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午前涨超4%，截至发稿，涨3.46%，报18.82港元，成交额2199.1万港元。消息面上，歌礼制药此前宣布启动ASC30_39FDC的临床开发，并计划于今年第三季度向美国FDA递交IND申请。口服剂型即将向FDA提交III期临床计划，公司预计将在2026年Q3正式启动。值得注意的是，智通财经APP在《歌礼制药-B：股价突破前高在即，场外资金为何选择观望？》中指出，礼来Orforglipron已于今年4月1日获FDA批准上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1191","BK4134","01672","BK4585","III","BK1515","VXUS","BK1574","BK4588","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096535","title":"康宁杰瑞制药-B(09966)：KN026新辅助治疗乳腺癌III期临床研究结果获选于2026 ASCO年会 LBA口头报告环节进行展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096535","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629096535?lang=zh_cn&edition=full","pubTime":"2026-04-22 12:03","pubTimestamp":1776830598,"startTime":"0","endTime":"0","summary":"KN026-004是一项随机、对照、开放、多中心III期临床研究，旨在评价KN026 联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗及多西他赛±卡铂在HER2阳性早期及局部晚期BC新辅助治疗中的疗效和安全性。KN026联合疗法有望成为HER2阳性早期及局部晚期BC新辅助治疗的全新标准疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","BK1574","BK1161","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628749960","title":"石药集团(01093)：注射用西罗莫司(白蛋白结合型)(HB1901)用于治疗晚期恶性血管周围上皮样细胞瘤(PEComa)的Ib / III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2628749960","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628749960?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:51","pubTimestamp":1776678667,"startTime":"0","endTime":"0","summary":"HB1901表现出优异疗效，有望填补国内该适应症治疗空白，成为国内晚期恶性PEComa首款标准治疗方案。约50 %的恶性PEComa患者确诊时已属晚期，此时常合并转移，预后差。HB1901 -004是一项旨在评价注射用西罗莫司在晚期恶性PEComa患者中安全性与有效性的Ib / III期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1152091168.USD","LU1226287875.USD","IE00B543WZ88.USD","III","LU1226287792.SGD","LU1226288170.HKD","BK1515","LU1807302812.USD","01093","IE0008369823.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","BK1521","BK1191","LU0501845795.SGD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1960683339.HKD","BK4134","LU2039709279.SGD","HK0000165453.HKD","LU0072913022.USD","LU1226287529.USD","SG9999004220.SGD","LU0140636845.USD","LU0314109678.HKD","LU1993786604.SGD","LU1951186391.HKD","LU0315179316.USD","IE0008368742.USD","LU0326950275.SGD","LU1008478684.HKD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU1226288253.USD","LU1328277881.USD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628615057","title":"轩竹生物-B(02575)：地罗阿克一线治疗ALK阳性晚期非小细胞肺癌III期临床研究数据于2026年AACR展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2628615057","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628615057?lang=zh_cn&edition=full","pubTime":"2026-04-19 18:17","pubTimestamp":1776593868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，集团已在2026年4月17日至2026年4月22日举行的2026年美国癌症研究协会年会以口头报告的形式展示地罗阿克一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的临床III期研究结果。DIAMOND-2研究是一项在中国境内开展的多中心、随机、开放标签的III期临床研究，以克唑替尼作为对照，旨在头对头评估地罗阿克相较克唑替尼在一线治疗ALK阳性晚期NSCLC患者的有效性与安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ALK","02575","BK4588","BK4585","BK4500","BK4008","BK1191","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628227042","title":"药捷安康-B(02617)：替恩戈替尼单药治疗晚期胆管癌患者确证性III期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2628227042","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628227042?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:41","pubTimestamp":1776422489,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)公布，公司核心产品替恩戈替尼(Tinengotinib, TT-00420)单药治疗晚期胆管癌患者的确证性III期临床研究，于近日完成首例患者给药。本试验为在中国开展的一项评价替恩戈替尼对比化疗用于既往经一线系统性治疗后复发或进展的、携带FGFR2融合╱重排或突变的、手术不可切除的晚期或转移性肝内胆管癌患者的疗效与安全性的随机对照、开放、多中心III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","III","02617","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627407539","title":"中国生物制药(01177)：维特柯妥拜单抗“CLDN18.2 ADC”一线胃及胃食管交界部腺癌III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627407539?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:02","pubTimestamp":1776243779,"startTime":"0","endTime":"0","summary":"本研究为LM-302开展的第二项Ⅲ期临床试验，也是全球首个CLDN18.2 ADC药物采用无化疗方案用于胃癌一线治疗的Ⅲ期临床试验。这种“ADC+免疫”联合策略有望为CLDN18.2阳性胃癌患者带来更深度的肿瘤缓解。除本次启动的LM-302联合疗法用于一线治疗CLDN18.2阳性GC/GEJ的III期临床外，LM-302单药用于三线及以上CLDN18.2阳性GC/GEJ的III期临床研究已完成全部受试者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK4134","BK1191","BK4231","BK1589","BK1521","HK0000165453.HKD","III","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","01177","IE00BZ08YR35.GBP","BK1515","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473918","title":"来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473918","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627473918?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:22","pubTimestamp":1776212528,"startTime":"0","endTime":"0","summary":"II期临床试验是一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。.每日一次口服LAE 002的治疗，患者耐受性良好，因不良事件而中止治疗的比例极低。本集团有权就许可区域内LAE 002的未来净销售额收取梯度销售分成，分成比率在十余个百分点至二十余个百分点。本集团计划在中国以外地区寻求战略合作伙伴，以加速LAE 002在国际市场的开发及商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PFS","BK4134","BK4195","III","02105","BK4211","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":0.0777},{"period":"1month","weight":0.0423},{"period":"3month","weight":-0.0672},{"period":"6month","weight":-0.1345},{"period":"1year","weight":-0.0533},{"period":"ytd","weight":-0.2318}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022101},{"month":2,"riseRate":0.5,"avgChangeRate":0.004642},{"month":3,"riseRate":0.315789,"avgChangeRate":0.030463},{"month":4,"riseRate":0.473684,"avgChangeRate":-0.00444},{"month":5,"riseRate":0.368421,"avgChangeRate":-0.022428},{"month":6,"riseRate":0.5,"avgChangeRate":0.015439},{"month":7,"riseRate":0.444444,"avgChangeRate":0.01427},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}